title: [A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
abstract: Frequently advanced or recurrent esophageal cancer was invasive trachea and often causing hemoptysis, stenosis and dyspnea. Occasionally, these cases were treated by a placement of tracheal stent. The placement effect was quickly and a main symptom of dyspnea was improved dramatically. However, the most of the cases were in poor prognosis with advanced cancer treated by chemo-radiotherapy (CRT). We experienced a case of recurrent esophageal cancer with tracheal invasion treated by placement of tracheal expandable metallic stent (EMS). A case was a 73-year-old man (at first admission). He was performed esophagectomy with tracheotomy against esophageal carcinoma at cervical portion. Eighteen month later, a local recurrence with tracheal invasion was appeared. The tracheal covered stent was inserted at the recurrent site. After stenting, CRT was performed with 5-FU and docetaxel. The effect of CRT was complete response (CR). Hence, a stent was removed from trachea. No recurrence was observed at the site and maintained a CR condition for two years after CRT.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Toshima Hospital.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ami
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagahama
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ando
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Watayou
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Amagasa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ganno
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Hataji
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kurokawa
authors.forename: Akira
authors.initials: A
authors.lastname: Fukuda
authors.forename: Shikofumi
authors.initials: S
authors.lastname: Tei
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Arai
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000628:therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction; D015607:Stents; D043823:Taxoids / Q000008:administration & dosage; D014132:Trachea / Q000473:pathology*; D014134:Tracheal Neoplasms / Q000473:pathology / Q000628:therapy*; D014135:Tracheal Stenosis / Q000628:therapy
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D005472:Fluorouracil